Acute Exacerbation of CRS Treatment Market Detailed in New Research Report
                     Acute Exacerbation of CRS Treatment Market: Introduction
According to the report, the global acute exacerbation of CRS treatment market was valued
over US$ 4.33 Bn in 2020. It is projected to expand at a CAGR of 4.6% from 2021 to 2031.
Rhinosinusitis is a major health issue globally. It is an infection of the nasal passages and
paranasal  sinuses.  It  has  three  cardinal  symptoms:  nasal  obstruction,  purulent  nasal
discharge, and facial pain-pressure-fullness. Nasal obstruction is defined by the patient as
obstruction,  congestion,  blockage,  or  stuffiness;  purulent  nasal  discharge  is  cloudy  or
colored  in  appearance;  and  facial  pain-pressure-fullness  involves  the  anterior  face  and
periorbital region or manifests with headache that can be localized or diffuse.
The  rise  in  cases  of  rhinosinusitis  is  expected  to  drive  the  acute  exacerbation  of  CRS
treatment  market  during  the  forecast  period.  According  to  the  CDC,
approximately 28.9 million adults were diagnosed with rhinosinusitis in the U.S.  in 2018.
Additionally, rhinosinusitis accounted for around 12 to 17 million annual visits to physicians
and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10
most common conditions to be treated in ambulatory practice. Hence, increase in cases of
acute  rhinosinusitis is  projected to fuel  the global  acute  exacerbation of  CRS treatment
market.
Request a PDF Brochure 
- https://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=82738
Acute Exacerbation of CRS Treatment Market Segmentation
In terms of treatment, the global acute exacerbation of CRS treatment market has been
segregated into treatment, route of administration, distribution channel, and infection type.
Treatment  consists  of  antibiotics,  leukotriene  inhibitors,  antihistamines,  mucolytics,
decongestants,  nasal  saline irrigation,  oral  corticosteroids, endoscopic sinus surgery,  and
others. The route of administration segment consists of topical, nasal, oral, and injectable.
In terms of distribution channel, the global acute exacerbation of CRS treatment market has
been split  into online pharmacies,  retail  pharmacies,  and hospital  pharmacies.  Based on
infection type, the global acute exacerbation of CRS treatment market has been categorized
into staphylococcus species and others.
In terms of treatment, the global acute exacerbation of CRS treatment market has been
segmented  into  antibiotics,  leukotriene  inhibitors,  antihistamines,  mucolytics,
decongestants,  nasal  saline irrigation,  oral  corticosteroids, endoscopic sinus surgery,  and
others.  The  antibiotics  segment  dominance  is  attributed  to  the  high  prescription  of
antibiotics in acute exacerbation of CRS by physicians.
Request for Analysis of COVID19 Impact on Acute Exacerbation of CRS Treatment Market- 
https://www.transparencymarketresearch.com/sample/sample.php?
flag=covid19&rep_id=82738
Acute Exacerbation of CRS Treatment Market Drivers
During the projected period, the acute exacerbation of CRS treatment market is anticipated
to be driven by an increase in instances of rhinosinusitis. For instance, The prevalence of
chronic  rhinosinusitis  (CRS)  worldwide  ranges  from  about 8% in  China, 8.4% in
Korea, 11% in Europe, and 12% in the U.S. As a result, the worldwide Acute Exacerbation of
CRS  Treatment  market  is  expected  to  grow  as  the  number  of  instances  of  chronic
rhinosinusitis rises.
Request a Sample of Acute Exacerbation of CRS Treatment Market: 
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82738
Regional Segmentation of Acute Exacerbation of CRS Treatment Market
North America dominated the global acute exacerbation of CRS treatment market in 2020,
and the trend is anticipated to continue during the forecast period. The U.S. is anticipated to
dominate the market in North America during the forecast period, owing to the presence of
a large number of key players, high healthcare expenditure, and reimbursement policies
favoring the usage of acute exacerbation of CRS treatment in the country.
Surge in healthcare expenditure and rise in awareness about sinusitis are anticipated to fuel
the market in Asia Pacific. The market in Asia Pacific is also projected to expand due to
robust healthcare expenditure on R&D of pharmaceutical drugs.
The market in Europe is anticipated to be driven by an increase in the demand for drugs for
the treatment of acute exacerbation of CRS. Additionally, increase in awareness regarding
acute exacerbation of CRS and focus on discovering novel treatment drugs are anticipated
to fuel the market in the region.
Enquiry before Buying Acute Exacerbation of CRS Treatment Market Report - 
https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82738
Competition Landscape
The  study  also  presents  profiles  of  leading  players  in  the  global  market  for  acute
exacerbation of  CRS treatment.  These include Sun Pharmaceutical  Industries,  Inc.,  Pfizer
Inc.,  Janssen  Pharmaceuticals,  Inc.  (Johnson  &  Johnson),  Fresenius  Kabi  USA,  LLC,  Dr.
Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott
Laboratories,  Bayer  AG,  Eli  Lilly  And  Company,  Bristol-Myers  Squibb,  Merck  & Co,  Inc.,
AstraZeneca  Plc,  Amneal  Pharmaceuticals  LLC,  GlaxoSmithKline  plc.,  Aurobindo  Pharma,
Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.    
Leading  companies  in  the  global  market  for  acute  exacerbation  of  CRS  treatment  are
focused on strengthening the distribution chain and expansion of the product range to gain
market  share.  For  instance,  on  July  26  2020,  Novartis  announced  that  the  European
Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a
positive opinion recommending the approval of Xolair (omalizumab) as an add-on therapy
with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP), for whom therapy with INC does
not provide adequate disease control. If approved, omalizumab would be the first treatment
for nasal polyps, specifically targeting and blocking immunoglobulin E (IgE), which helps to
reduce  the  size  of  nasal  polyps  (as  defined  by  Nasal  Polyps  Score;  NPS)  and  improve
symptoms.
More Trending Reports by Transparency Market Research:
Topical Pain Management Therapeutics in Sports Medicine Market- 
https://www.transparencymarketresearch.com/topical-pain-management-therapeutics-
sports-medicine-market.html
Alpha 1 Antitrypsin Deficiency Treatment Market- 
https://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-
market.html
Sterilization Equipment and Disinfectant Market- 
https://www.transparencymarketresearch.com/sterilization-equipment-market.html
Wound Debridement Market- https://www.transparencymarketresearch.com/wound-
debridement-market.html
Ophthalmic Drugs Market- https://www.transparencymarketresearch.com/ophthalmic-
drugs-market.html
Respiratory Disorders Treatment Market- 
https://www.transparencymarketresearch.com/respiratory-disorders-treatment-
market.html
Cryptococcosis Market- https://www.transparencymarketresearch.com/cryptococcosis-
market.html
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market- 
https://www.transparencymarketresearch.com/non-alcoholic-steatohepatitis-biomarkers-
market.html
About Us 
Transparency  Market  Research,  a  global  market  research  company  registered  at
Wilmington, Delaware, United States, provides custom research and consulting services. The
firm scrutinizes factors shaping the dynamics of demand in various markets. The insights
and  perspectives  on  the  markets  evaluate  opportunities  in  various  segments.  The
opportunities in the segments based on source, application, demographics, sales channel,
and  end-use  are  analysed,  which  will  determine  growth  in  the  markets  over  the  next
decade.
 
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking
insights for thousands of decision-makers, made possible by experienced teams of Analysts,
Researchers, and Consultants. The proprietary data sources and various tools & techniques
we use always reflect the latest trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary and secondary research
techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit 
subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-
TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]